Dear Ms. Dhalla:

Please refer to your new supplemental new drug application (NDA) dated July 31, 2007, received August 6, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Xyzal (levocetirizine dihydrochloride) 5mg tablets.

These “Changes Being Effected” supplemental new drug application provides for editorial revisions and for changes to the HOW SUPPLIED/STORAGE AND HANDLING section of the Full Prescribing Information (FPI).

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on July 31, 2007.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
HFD-001, Suite 5100
5515 Security Lane
Rockville, MD 20852

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lori Garcia, Senior Regulatory Management Officer, at (301) 796-1212.
Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary and Allergy Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Badrul Chowdhury
2/1/2008 12:03:15 PM